Saturday 17 October 2026 Export ECOR’s income statement to Excel — free account

electroCore, Inc.

electroCore, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32.0 million, up 27.2% from fiscal 2024. In the quarter to June 2026, revenue grew 28.0%, EPS grew 25.0% and free cash flow fell 443.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

7.85 0.50 −5.99%

Follow ECOR

Alert me

Market cap: $75.3M
P/E: 0.0×
Fwd P/E: −5.8×
Dividend yield: —
F-score: 3/9
Altman Z: −13.54
Beneish M: −4.52
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.21

Total sells 0.95

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	1	—	—	—	—	1	—	—	1	2	—
Sell	1	1	—	—	—	2	2	—	—	1	—	—

Insider Ownership 35.67%

Capital & Financial Ratios $m

Market Cap 75.28

Revenue 36.97

Net Income (14.77)

Free Cash Flow (9.74)

Net Debt (4.28)

Current Ratio 1.21

Debt/Equity (2.07)

P/E ratio 0.00

Fwd P/E (5.81)

P/S ratio 2.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 16.61%

Next Y EPS Growth 54.76%

Next Y revenue growth 30.87%

Next 5Y EPS Growth 68.82%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 15.92%

10-year low 10-year high

EV/Sales against its own 10 years 42.41%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	11	12	12	10
Receivables	1	1	1	1
Inventory	2	2	2	2
Other	—	—	—	—
	14	16	16	14

	2023	2024	2025	Q'26
Payables	2	2	3	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	8	9	11	12

Compound Annual Growth %

	10y	5y	3y
Sales	—	55.74%	55.06%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	10	9	—	—	—
’25	7	7	9	9	32
’24	5	6	7	7	25
’23	3	4	5	5	16
’22	2	2	2	3	9
’21	1	1	1	1	5
’20	1	1	1	1	3

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(4)	—	—	—
’25	(4)	(1)	(2)	(2)	(8)
’24	(3)	(2)	(1)	(1)	(7)
’23	(6)	(3)	(2)	(3)	(15)
’22	(5)	(3)	(5)	(4)	(17)
’21	(4)	(2)	(3)	(4)	(14)
’20	(8)	(4)	(4)	(4)	(20)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(4)	—	—	—
’25	(4)	(1)	(2)	(2)	(8)
’24	(3)	(2)	(1)	(1)	(7)
’23	(6)	(3)	(2)	(3)	(15)
’22	(5)	(3)	(5)	(4)	(17)
’21	(4)	(2)	(3)	(4)	(14)
’20	(8)	(4)	(4)	(4)	(20)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.59)	(0.33)	—	—	—
’25	(0.47)	(0.44)	(0.40)	(0.34)	(1.65)
’24	(0.53)	(0.38)	(0.31)	(0.40)	(1.59)
’23	(1.24)	(1.03)	(0.68)	(0.61)	(3.42)
’22	(1.20)	(1.20)	(1.20)	(1.22)	(4.69)
’21	(1.65)	(0.90)	(0.90)	(1.05)	(4.35)
’20	(4.05)	(1.95)	(1.50)	(2.10)	(9.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	62.40	17.40	4.80	8.60	2.93	3.10	5.32	4.16	Analyst estimates 2026–2028 Powerpack
	High	—	—	303.75	153.68	49.50	54.45	14.70	7.50	17.89	19.49
People
People	Employees	—	64	91	51	45	52	62	68	73	83
	Revenue/emp, $m	0.00	0.01	0.01	0.05	0.08	0.10	0.14	0.24	0.34	0.39
Income, $m
Income, $m	Revenue	0	1	1	2	3	5	9	16	25	32
	Gross margin, %	51.32	36.09	41.71	51.60	50.30	74.59	81.19	82.51	84.97	86.75
	EBT	(16)	(36)	(56)	(45)	(25)	(18)	(23)	(19)	(12)	(14)
	EBT margin, %	(6,210.74)	(4,439.78)	(5,615.61)	(1,888.06)	(706.04)	(331.48)	(262.95)	(118.65)	(47.57)	(43.59)
	Net income	(16)	(36)	(56)	(45)	(24)	(17)	(22)	(19)	(12)	(14)
	Depreciation	1	6	0	0	0	1	1	1	1	1
Per share, $
Per share, $	Revenue	0.03	0.00	0.51	1.22	1.34	1.38	1.82	2.91	3.37	3.78
	Earnings	(1.57)	(1.27)	(28.57)	(23.09)	(9.00)	(4.35)	(4.69)	(3.42)	(1.59)	(1.65)
	Cash flow	(1.32)	0.00	(24.14)	(23.00)	(7.71)	(3.45)	(3.52)	(2.66)	(0.93)	(0.97)
	Capex	0.00	0.00	(0.14)	(0.04)	0.00	0.00	0.00	(0.04)	0.00	(0.01)
	Free cash flow	(1.32)	0.00	(24.28)	(23.03)	(7.71)	(3.45)	(3.52)	(2.70)	(0.93)	(0.97)
	Book value	(0.75)	0.00	33.91	12.71	9.09	9.29	3.61	1.35	1.01	(0.20)
	Shares, m	10	0	2	2	3	4	5	6	7	8
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	0.00	184.57	19.55	17.41	6.33	2.20	2.05	4.82	1.19
	P/B	0.00	0.00	2.77	1.88	2.57	0.94	1.10	4.42	16.08	0.00
	EV/Sales	0.00	0.00	119.69	10.33	11.54	0.11	0.19	1.43	4.36	1.04
	EV/FCF	(0.11)	(0.11)	(2.51)	(0.55)	(2.01)	(0.04)	(0.10)	(1.55)	(15.34)	(4.02)
Cash, $m
Cash, $m	Operating cash flow	(13)	(25)	(47)	(45)	(20)	(14)	(17)	(15)	(7)	(8)
	Capex	—	0	0	0	—	—	—	0	—	0
	Free cash flow	(13)	(25)	(47)	(45)	(20)	(14)	(17)	(15)	(7)	(8)
Balance, $m
Balance, $m	Working capital	(4)	33	66	17	19	32	14	6	7	4
	Total debt	4	2	—	1	1	1	1	—	—	7
	Net debt	4	(35)	(69)	(23)	(22)	(34)	(17)	(11)	(12)	(5)
	Shareholders’ equity	(8)	33	66	25	24	37	17	7	8	(2)
Returns, %
Returns, %	ROA	(78.97)	0.00	(61.56)	(82.87)	(70.20)	(46.32)	(65.58)	(92.19)	(65.00)	(71.37)
	ROIC	0.00	0.00	0.00	(1,275.76)	(731.55)	(471.20)	0.00	0.00	0.00	0.00
	ROE	20.83	0.00	298.10	(99.14)	(96.87)	(57.11)	(82.49)	(153.57)	(158.63)	(478.70)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
APYX Apyx Medical Corporation	$107.8M	— (loss-making)	— (loss-making)	+22.08% (above 0%: growing)	n/m	−137.38% (below 0%: shrinking)	63.89%	(13.01%)	Compare
LUCD Lucid Diagnostics Inc.	$105.7M	— (loss-making)	— (loss-making)	+26.74% (above 0%: growing)	n/m	−7.04% (below 0%: shrinking)	1.97%	(868.45%)	Compare
ZOMDF Zomedica Corp.	$95.4M	— (loss-making)	— (loss-making)	+36.59% (above 0%: growing)	n/m	+40.48% (above 0%: growing)	63.51%	(42.92%)	Compare
HYPR Hyperfine, Inc.	$82.7M	— (loss-making)	— (loss-making)	+44.81% (above 0%: growing)	n/m	+13.43% (above 0%: growing)	50.72%	(216.93%)	Compare
SERA Sera Prognostics, Inc.	$80.1M	— (loss-making)	— (loss-making)	+76.47% (above 0%: growing)	n/m	−10.58% (below 0%: shrinking)	(66.67%)	(33,346.67%)	Compare
LUNG Pulmonx Corporation	$79.5M	— (loss-making)	— (loss-making)	−4.62% (below 0%: shrinking)	n/m	−31.79% (below 0%: shrinking)	77.97%	(39.80%)	Compare
OM Outset Medical, Inc.	$76.6M	— (loss-making)	— (loss-making)	+0.69% (above 0%: growing)	n/m	−90.54% (below 0%: shrinking)	41.99%	(49.55%)	Compare
ECOR electroCore, Inc.	$75.3M	— (loss-making)	— (loss-making)	+28.03% (above 0%: growing)	n/m	−443.52% (below 0%: shrinking)	86.53%	(29.33%)
LNSR LENSAR, Inc.	$74.1M	2.0×	7.1×	+18.37% (above 0%: growing)	n/m	+96.81% (above 0%: growing)	59.27%	12.94%	Compare
Median of peers	$81.4M	—	—	+24.41%	—	−8.81%	54.99%	(46.24%)

All 149 Medical Devices stocks →

electroCore, Inc. (ECOR) key facts

Strength: electroCore, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32.0 million, up 27.2% from fiscal 2024.
electroCore, Inc. (ECOR) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ECOR traded at $7.85, a market capitalization of $75.3 million.
Return on equity was −478.7% and debt-to-equity -2.07.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −13.54 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.